Summary
- Summary pending editorial review.
Key Facts
- Key facts pending editorial review.
Sources
Updates
Update at 13:29 UTC on 2026-03-11
STAT reported Recent developments highlight the FDA's warning to Novo Nordisk and Lilly's strategic investments in China.
Sources: STAT